Abbott to split Nutrition into independent company with $8.5 billion in sales by end of 2027
Abbott announced plans to separate its Nutrition business into a standalone publicly traded company by the...
GE Aerospace raises 2026 guidance as commercial services orders surge 58 percent
GE Aerospace lifted full-year profit and cash flow targets after third-quarter orders jumped 58 percent, driven...
Biohaven licenses Japan and Asia rights to Graves’ disease candidate for $80 million upfront and 20% royalties
Biohaven has licensed its lead extracellular IgG degrader, BHV-1300, to Ono Pharmaceutical for exclusive development and...
UnitedHealth’s operating margin surges as medical cost discipline offsets revenue decline
UnitedHealth Group raised full-year earnings guidance to at least $20.50 per share after third-quarter operating earnings...
JPMorgan Chase’s third-quarter profit falls 28 percent as revenue slumps and credit costs rise
JPMorgan Chase reported net income of $15,305 million in the third quarter of 2026, down 28...
Delta’s September quarter revenue surges 16 percent on yield growth as fuel costs eat into margins
Delta Air Lines posted September quarter revenue of $17.6 billion, up 16 percent from the prior...
Viatris Acquires Pacira for $1.65 Billion to Build Non-Opioid Pain Portfolio
Viatris agreed to acquire Pacira BioSciences for $36.50 per share in cash, an aggregate equity value...
PepsiCo’s organic growth accelerates to 3.1% as international volume offsets North America pricing pressure
PepsiCo's third-quarter organic revenue growth jumped to 3.1%, up from 2.7% year-to-date, driven by volume gains...
Caribou Biosciences halts CAR-T programs and explores sale as financing dries up
Caribou Biosciences announced it is evaluating strategic alternatives, including a merger or sale, and will discontinue...
Regeneron secures $1 billion upfront and profit-share deal with Sanofi on four new antibodies
Regeneron and Sanofi have expanded their 17-year collaboration to co-develop and co-commercialize four new long-acting antibodies...
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.